PC
ATRA icon

PointState Capital’s Atara Biotherapeutics ATRA Stock Holding History

PointState Capital’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,880
Closed -$11.6M – 159
2018
Q1 		$11.6M Buy
+11,880
New +$10.8M 0.13% 90

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

PointState Capital's ATRA Position: Q2 2018 in Review

PointState Capital sold out of Atara Biotherapeutics (ATRA) in Q2 2018, closing a stake of 11,880 shares — an estimated $11.6M sold.

PointState Capital first reported a position in ATRA in Q1 2018 and held it in 1 quarter. The position peaked at $11.6M in Q1 2018. 124 funds tracked by Wall St. Rank hold ATRA as of Q2 2018.

  • PointState Capital reported no remaining Atara Biotherapeutics position as of Q2 2018 after selling out during the quarter.
  • PointState Capital sold 11,880 Atara Biotherapeutics shares in Q2 2018, an estimated $11.6M.
  • PointState Capital first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 1 quarter.
  • PointState Capital's Atara Biotherapeutics position peaked at $11.6M in Q1 2018.
  • 124 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2018.

Based on PointState Capital's 13F filing for Q2 2018, filed 14 Aug 2018.